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Abstract: : Chagas disease or American trypanosomiasis is a neglected tropical disease caused by the parasite 
Trypanosoma cruzi. Although the number of infected individuals has decreased, about 6-7 million people are 
infected worldwide. The chemotherapy drugs currently used are limited to benznidazole and nifurtimox. They 
are effective in acute phase, congenital transmission and children with chronic infection; however, recent 
clinical trials have shown limitations in adults with chronic infection, presenting drawbacks during the 
treatment. Thus, there is an urgent need for new effective, safe and affordable drugs to fight against this 
complex disease. There were high expectations for azole derivatives as they appeared to be the most 
promising drugs for the treatment of Chagas disease during the last decade; however, the disappointing results 
obtained so far in clinical trials evidenced the lack of correlation between preclinical and clinical 
development. Therefore, the feedback obtained from these studies should define the starting point for 
addressing a roadmap for the drug discovery process in the fight against this disease. To tackle this challenge, 
it is important to keep in mind the drug target profile, already defined by panels of experts, and the 
coordinated work involving multi-disciplinary networks focusing not only on the discovery of new drugs but 
also on the standardization of the protocols that would allow acceleration in the Chagas disease drug 
discovery process. 
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